SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2023

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2023

Paris, April 11, 2023 – SparingVision (“the Company”), a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces

announces today that it has been selected for three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting to be held from 23-27 April.

 

Poster Presentation: Nonclinical safety and pharmacokinetic assessment of SPVN06, an AAV-based gene therapy for the treatment of rod-cone dystrophies

Date and Time: 23 April, 12:00 – 2:00 PM, Poster #773 – C0374

Presenter: Anne-Sophie Gautron, PhD

Session Title: Gene therapy and gene editing for ocular disorders

Session Number: 140

 

Poster Presentation: Mouse model selection for pharmacological evaluation of AAV-based therapeutic agents for the treatment of rod-cone dystrophies (RCD)

Date and Time: 25 April, 8:45 AM – 10:45 AM, Poster #2591 – B0304

Presenter: Melanie Marie, PhD

Session Title: Retina/RPE: New drugs, mechanisms of action and toxicity

Session Number: 320

 

Poster Presentation: Mobility and postural testing in patients with rod-cone dystrophy enrolled in the prospective natural history study PHENOROD2
Date and Time: 26 April, 2:15 – 4:15 PM, Poster #4644 – C0109

Presenter: Mylène Poujade

Session Title: Retinitis pigmentosa

Session Number: 450

**ENDS**